The researchers state that although the study was completed in 1995, the data are being published now due to the efforts of the authors and Marathon Pharmaceuticals since the original sponsor of the study gave up the rights to the data and compound. Marathon submitted a New Drug Application in 2016 for US approval of deflazacort for the treatment of Duchenne muscular dystrophy.